Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) —Significant clinical and regulatory progress across entire pipelineBV100:Initiated global registrational Phase 3 (RIV-TARGET) in HABP/VABP1 program – US FDA green lights IND Phase 2b (RIV-CARE) to be conducted via Wellcome-funded trial network ADVANCE-ID First participants dosed in Phase 1 in China, preparing onboarding of China into RIV-TARGET BV100 patent granted in China, adding to BV100’s patent coverage in over 25 countries including the US and EuropeAlpibectir:Our partner GSK reported first patient first visit for Phase 2b/c trial in pulmonary TB Phase 2a results published in New England Journal of Medicine Received EMA Orphan DesignationCorporate:BV500: Entered global research collaboration with Shionogi for...

IRVINE, Calif., March 17, 2026 (GLOBE NEWSWIRE) — Phoenix Energy One, LLC (NYSE American, PHXE.P) (“Phoenix Energy” or the “Company”), an energy company focused on oil and gas exploration and production across key U.S. basins, with a primary footprint in the Williston Basin in North Dakota and Montana, filed its Annual Report for the fiscal year ended December 31, 2025 on March 17, 2026, thereby announcing its financial and operating results for the fourth quarter and full year of 2025. The Company delivered strong year-over-year growth in revenue, net income, and production as it expanded operations across key U.S. basins. Q4 2025 Highlights Phoenix Energy delivered record quarterly production and more than doubled revenue compared with the fourth quarter of 2024.Generated revenue of $218.6 million (an increase of 115% from Q4...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential During the fourth quarter, Silexion achieved key clinical readiness milestones including completing two-species toxicology studies, written Scientific Advice from Germany’s BfArM, and submission of Phase 2/3 clinical trial application to the Ministry of Health in Israel for SIL204 in locally advanced pancreatic cancer The Company remains on track to initiate Phase 2/3 clinical trial in the first half of 2026, with Israel regulatory feedback anticipated by the end of Q1 2026 Grand Cayman, Cayman Islands, March 17, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion”...

GREENWICH, Conn., March 17, 2026 (GLOBE NEWSWIRE) — Stardust Power Inc. (Nasdaq: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium carbonate, today announced its preliminary results for the year ended December 31, 2025 and provided an update on the continued development of its lithium refinery project in Muskogee, Oklahoma. “2025 marked a year of meaningful progress for Stardust Power as we advanced the technical, commercial and regulatory foundations of our lithium refinery in Muskogee,” said Roshan Pujari, Founder and Chief Executive Officer of Stardust Power. “During the year, we completed key engineering milestones, including our FEL-3 study, entered into strategic feedstock supply agreements and received independent third-party validation of the refinery design. Phase I is expected to...

2025 Was a Transformative Year due to Merger Completed in Q3 OLD GREENWICH, Conn., March 17, 2026 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) (“Star” or the “Company”), a diversified holding company, announced today financial results for the fourth quarter and full year ended December 31, 2025. 2025 Fourth Quarter SummaryRevenue of $56.8 million increased 69% from the fourth quarter of 2024. Gross profit of $24.2 million increased 38% from the fourth quarter of 2024. Net loss attributable to common shareholders of $2.4 million, or $0.67 loss per diluted share, versus net loss attributable to common shareholders of $0.6 million, or $0.20 loss per diluted share, in the fourth quarter of 2024. Adjusted net loss attributable to common shareholders per diluted share (Non-GAAP measure)*...

2025 Revenue: $31.8 million, 34% YoY increase2025 Transaction Volumes of $960 million, 46% YoY increaseLaunch of Fold Bitcoin Credit Card and Enterprise ServicesRetired convertible notes, Streamlined capital for growth PHOENIX, March 17, 2026 (GLOBE NEWSWIRE) — Fold Holdings, Inc. (NASDAQ: FLD) (“Fold”, “we”, or “our”), the first publicly traded bitcoin financial services company, today announced financial results for the fourth quarter and full year ended December 31, 2025. FY 2025 Financial HighlightsRevenue: $31.8 million; 34% YoY increase Operating Loss: ($27.7) million Adjusted EBITDA2 (Loss): ($17.2) million Loss Per Share: ($1.65) per share Adjusted EBITDA (Loss) Per Share2: ($0.41) per share Bitcoin Investment Treasury Holdings1: 1,527 BTCFY 2025 Key Operating MetricsTotal Transaction Volume: $960 million; 46% YoY...

Record Backlog and Strategic DHS Win Accelerate Maritime Defense Platform Strategy MONROE TOWNSHIP, N.J., March 17, 2026 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), today announced financial results, including record backlog, for its fiscal third quarter (“3Q26”) ended January 31, 2026. Highlights include: 3Q26 RESULTS and RECENT HIGHLIGHTSOPT secured a multi-buoy contract totaling approximately $6.5 million from the U.S. Department of Homeland Security (“DHS”) supporting a U.S. Coast Guard maritime domain awareness mission off San Diego. The award provides multi-quarter revenue visibility, with delivery of four newly built MERROWS®-equipped PowerBuoy® systems beginning in Q4 of fiscal 2026. The contract further advances our shift toward higher-margin,...

 Public release of Virbac Consolidated Accounts at 31 December 2025. The Group released its 2025 Consolidated Accounts. The document is available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports”. The accounts were audited by the statutory auditors and examined by the board of directors on March 17, 2026. The report of the statutory auditors is in the process of being issued.AttachmentVirbac consolidated Accounts_31 December 2025

A robust adjusted EBIT margin² of 16.3% at CERS, driven by solid organic revenue growth of 7.9%Solid 2025 dynamic with annual revenue up +7.9% at CERS; with strong momentum in key categories and countries. Volume/mix effect of ~+5%, completed by price increase of ~+3% Adjusted EBIT (before amortization of assets arising from acquisitions) margin of 16.3% at CERS despite:temporary shutdown of an antigen’s production site and higher inventory write-offs in FY25 partially offset by a solid underlying performance on sales prices and product mix and; improving operating expense to revenue ratio. Consolidated net income increased by +3.2% and amounts to €150.5m Strong cash generation of €93 million funded the Thyronorm acquisition while maintaining a relatively stable net debt at €172.8 million compared to €168.5 million at the end of...

                                                                         COMPAGNIE DE L’ODETResults for fiscal year 2025 March 17, 2026  Net profit, Group share: €218 million Proposal to pay a dividend of €4.80 per share, an increase of 9% Revenue: €2,924 million, -9% at constant scope and exchange rates. Adjusted operating income (EBITA (1) (2)): €282 million including the results of the equity-accounted associates UMG, Canal+, Louis Hachette Group, Havas and Vivendi for the full year 2025. Net income: €354 million, compared with €1,750 million in 2024, which included the net capital gain on the disposal of Bolloré Logistics (+€3.7 billion) and the capital loss on the deconsolidation of companies resulting from the spin-off of Vivendi (-€1.9 billion). Net income, Group share: €218 million. Net cash position: €5,126 million...